Early Cryoablation After First Diagnosis of Atrial Fibrillation Reduces Arrhythmia Recurrence in Heart Failure
Monami Ando1, Satoshi Yanagisawa2,3, Hirohiko Suzuki1
1Department of Cardiology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Insights
Early cryoballoon ablation for atrial fibrillation (AF) in heart failure (HF) patients significantly lowers recurrence risk. This approach may improve clinical outcomes for individuals with coexisting AF and HF.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Device Technology
Background:
- Atrial fibrillation (AF) and heart failure (HF) frequently coexist, contributing to increased patient mortality.
- Cryoballoon ablation presents a safe and effective treatment option for AF in patients with HF.
Purpose of the Study:
- To determine the optimal timing for cryoballoon ablation following the initial diagnosis of AF in patients with HF.
- To evaluate the prognostic impact of cryoballoon ablation timing on clinical outcomes in this patient population.
Main Methods:
- A large-scale, multicenter retrospective study involving 543 patients with HF who underwent cryoballoon ablation for AF across 17 Japanese institutions.
- Patients were stratified into two groups based on ablation timing relative to AF diagnosis: early (≤0.5 years) versus delayed (>0.5 years).
- Clinical endpoints including AF recurrence, mortality, and HF hospitalization were compared between the early and delayed ablation groups.
Main Results:
- The early ablation group (≤0.5 years) demonstrated a significantly lower AF recurrence rate (24%) compared to the delayed group (>0.5 years) (34%; P=0.018).
- Early ablation (≤0.5 years) was independently associated with a reduced risk of recurrence (HR: 0.581; P=0.004).
- Delayed cryoballoon ablation was linked to an increased risk of post-ablation recurrence and was associated with antiarrhythmic drug use.
Conclusions:
- Performing cryoballoon ablation for AF early in patients with HF is associated with a reduced risk of recurrence.
- Timely cryoballoon ablation may offer a strategy to improve the clinical management of patients experiencing both AF and HF.
Background:
Atrial fibrillation (AF) and heart failure (HF) often coexist, leading to increased mortality. A cryoballoon-based approach is a potential treatment for patients with HF because of its safety and efficacy.
Objectives:
The authors sought to evaluate the optimal timing of cryoballoon ablation after the first clinical diagnosis of AF and its prognosis for patients with HF.
Methods:
This large-scale multicenter study retrospectively collected data of patients with HF who underwent cryoballoon ablation for AF from 17 Japanese institutions. Patients were divided into 2 groups depending on the duration between the first diagnosis and ablation using a median time of 0.5 year (IQR: 0.3-2.0 years). Clinical endpoints of recurrence, mortality, and HF hospitalization were compared between the 2 groups.
Results:
Among 3,655 patients, 543 with HF were included for analysis. During a median follow-up period of 21.3 months (IQR: 12.0-36.8 months), 151 of 520 patients (29%) had a recurrence. The AF recurrence rate was significantly lower in the early-ablation group (≤0.5 year) than in the delayed-ablation group (>0.5 year) (24% [65/266] vs 34% [86/254], respectively; P = 0.018). In the multivariable analysis, early ablation ≤ 0.5 year was independently associated with an absence of recurrence (HR: 0.581; 95% CI: 0.401-0.842; P = 0.004). Delayed time for cryoballoon ablation incrementally increased the risk of postablation recurrence. Antiarrhythmic drug use was independently associated with delayed ablation. No significant differences in mortality or HF hospitalization were observed between the 2 groups.
Conclusions:
Early cryoablation reduced the risk of recurrence in patients with HF, which may help improve clinical management.
Related Concept Videos
01:28Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:28Mechanism of Cardiac Arrhythmias
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers